Nisoldipine
As of the edition of 20 October 2026, Nisoldipine is a small molecule: marketed, first approved in 1995 (US); acts on CACNA1C, CACNA1D and CACNA1F and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Sular
- First approved
- 2 February 1995 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Azurity Pharmaceuticals
- Registered trials
- 3, 0 stopped early
- Disease areas
- Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Nisoldipine.
See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Azurity Pharmaceuticals | Acquired holder | 2026 to now |
| AstraZeneca | Originator | 1995 to 2026 |